Ipsen S.A./€IPN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Ipsen S.A.

Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.

Ticker

€IPN
Sector

Primary listing

PAR

Employees

5,358

Ipsen S.A. Metrics

BasicAdvanced
€9.6B
21.59
€5.37
0.19
€1.40
1.21%

Bulls say / Bears say

Ipsen reported H1 2025 total sales growth of 11.4% at constant exchange rates, core operating income up 21.9%, and expanded core margin by 3.6 points, prompting an upgrade to full-year guidance of >7% sales growth and >32% margin (Nasdaqturn1search0)
The Rare Disease segment surged 95.7% in H1 2025, with high-margin products Iqirvo and Bylvay delivering double-digit growth (Bylvay +63% YoY), underscoring Ipsen’s successful focus on niche specialty care (Nasdaqturn1search0turn3search1)
On 23 July 2025, the European Commission approved Cabometyx for previously treated advanced neuroendocrine tumors—Ipsen’s sixth indication for the drug—broadening its oncology franchise and diversifying revenue streams (Nasdaqturn1search0)
Somatuline, Ipsen’s long‐standing revenue driver, faces increasing generic competition in the U.S. and Europe, which management expects will negatively impact sales and margins in the second half of 2025 (Nasdaqturn1search0)
Ipsen’s future growth heavily depends on late‐stage clinical readouts for fidrisertib (FALKON trial) and its long‐acting neurotoxin (LANTIC trial), with negative or delayed results posing substantial downside risk to pipeline valuation and revenue forecasts (AInvestturn6search2)
On an IFRS basis, Ipsen’s FY 2024 consolidated net profit plunged 46.3% year-on-year to €347.3 m, reflecting impairments and non-core charges that signal volatility in reported earnings and potential impacts on cash flow (Ipsen Press Releaseturn7search1)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €IPN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs
Buy Ipsen S.A. stock | €IPN Share Price | Lightyear